1. China Stocks

  2. •

    Producer manufacturing

  3. •

    Industrial machinery
CGN Nuclear Technology Development Co. Ltd. Class A

CGN Nuclear Technology Development Co. Ltd. Class A

SSZSE:000881
6.36
CNY
-0.07
(-1.09%)
-0.39EPS
6.13BMarket Cap
Oct 30Next Earn
CGN Nuclear Technology Development Co. Ltd. Class A
SZSE:000881
(Shenzhen Stock Exchange)

Recent

price

6.36

P/E

ratio

- -

div

yld

1.02%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
5.64
5.58
8.62
6.45
6.49
4.6
6.31
6.03
6.49
6.85
7.04
8.46
7.35
6.72
6.52
5.87
5.89
Revenue per Share
0.66
0.74
0.65
0.35
0.24
0.53
0.65
0.37
0.31
0.1
0.29
0.19
0.21
-0.78
-0.38
-0.3
-0.36
Basic EPS, GAAP
-2.75
-3.56
1.82
1
-2.14
-0.43
-0.21
- -
-0.19
0.32
-0.26
-0.09
0.3
-0.07
-0.09
-0.22
- -
Free Cash Flow per Basic Share
0.44
0.64
0.66
0.46
0.51
0.04
0.06
0.19
0.2
0.19
0.12
0.21
0.21
0.13
0.1
0.07
0.06
Dividend per Share
4.18
4.47
5.01
5.16
5.31
3.88
16.57
5.07
5.5
6.06
6.31
6.45
6.69
5.91
5.53
5.33
5.2
Book Value per Share
4.16
4.45
5.01
5.16
5.3
2.37
14.71
4.3
4.62
5.07
5.32
4.8
5.01
4.25
3.84
3.72
3.61
Tangible Book Value per Share
309
309
309
310
313
465
479
1,056
1,045
1,025
945
946
945
945
945
945
945
Basic Weighted Avg Shares
1,742
1,722
2,665
1,998
2,030
2,137
3,023
6,369
6,784
7,022
6,652
7,999
6,945
6,353
6,168
5,553
5,571
Sales/Revenue/Turnover
18.16
13.48
10.86
3.92
5.03
11.77
11.33
9.13
7.59
3.71
6.76
8.66
5.38
-3.63
-2.21
-1.81
-2.24
Operating Margin (%)
68
130
153
148
146
34
45
168
177
216
246
320
482
484
382
353
- -
Depreciation Expense
203
230
201
108
75
245
312
389
320
103
271
177
200
-737
-362
-287
-342
Net Income, GAAP
8.37
13.57
22.03
26.6
14.24
15.12
13.35
11.69
6.33
9.85
13.38
- -
7.45
- -
- -
- -
- -
Effective Tax Rate (%)
11.67
13.36
7.54
5.42
3.7
11.49
10.32
6.11
4.71
1.46
4.08
2.21
2.87
-11.6
-5.87
-5.17
-6.13
Profit Margin (%)
545
282
481
880
509
436
3,452
2,999
3,383
3,139
3,285
3,339
2,928
2,234
2,989
2,288
2,145
Working Capital
1,061
1,388
1,283
1,587
1,052
77
1,176
662
926
460
1,021
1,210
621
882
1,597
705
635
LT Debt
1,856
2,003
2,212
2,227
2,280
1,216
5,214
5,575
6,049
6,163
6,416
6,675
6,742
6,030
5,548
5,719
5,571
Total Equity
9.08
6.99
5.92
1.76
0.99
6.19
5.18
4.83
3.32
0.67
2.84
- -
4.01
- -
- -
- -
- -
Return on Invested Capital (%)
5.07
5.44
4.97
3.47
1.93
9.28
6.5
5.36
4.3
2.24
3.82
- -
1.53
- -
- -
- -
- -
Return on Capital (%)
16.38
17.2
13.71
6.89
4.64
17.3
9.88
7.43
5.82
1.81
4.64
2.93
3.21
-12.38
-6.7
-5.59
-6.78
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,261
2,221
2,278
LT Borrowings
556
537
488
LT Finance Leases
150
142
148
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
945
945
945
Market Capitalization
8,556
7,251
6,126

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5,938
5,784
5,995
Cash, Cash Equivalents & STI
1,508
1,408
1,413
Accounts Receivable, Net
1,957
1,741
1,951
Inventories
1,130
1,217
1,332
Total Current Liabilities
3,650
3,550
3,851
Payables & Accruals
- -
- -
- -
ST Debt
2,261
2,221
2,278
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
33.99%
-2.08%
3.07%
Free Cash Flow
4,979.27%
-95.59%
141.02%
Net Income, GAAP
-43.27%
-112.56%
-20.73%
Sales/Revenue/Turnover
14.26%
-2.87%
-9.97%
Total Cash Common Dividend
58.05%
-3.28%
-23.89%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,310
1,518
1,630
1,711
6,168
2025
1,061
1,532
- -
1,488
5,553
2026
1,081
1,470
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.07
-0.02
-0.05
-0.24
-0.38
2025
-0.07
-0.04
- -
-0.2
-0.3
2026
-0.06
-0.07
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.03
0.01
0.03
0.1
2025
0.02
0.02
- -
0.02
0.07
2026
0.02
0.02
- -
- -
- -
Similar Companies
Applied Materials, Inc. (NASDAQ:AMAT)
Oklo Inc. (NYSE:OKLO)
Lam Research Corporation (NASDAQ:LRCX)
Tokyo Electron Ltd. (TSE:8035)
Welspun Corp Limited (NSE:WELCORP)
Symbotic Inc. (NASDAQ:SYM)
Business
CGN Nuclear Technology Development Co., Ltd. is a China-based company principally engaged in manufacturing cable materials, industrial electron accelerators, and proton therapy tumor system equipment, including raw materials and parts. Its core product portfolio includes ground nanoaccelerators, electronic curtain accelerators, DG resonant transformer accelerators, industrial flaw detection accelerators, and proton therapy systems with annual production capacity of about four units. The company also provides electron beam irradiation processing services, specializing in electron beam treatment of specialty waste, antibiotic residue treatment technology, pharmaceutical wastewater treatment, medical sewage and solid waste disposal, park sewage treatment, printing and dyeing wastewater treatment, coal chemical coking wastewater treatment, chemical wastewater treatment, domestic sewage treatment, and hazardous waste concentrate treatment. Additionally, it offers irradiated and synthetic materials such as modified polycarbonate, polyester, polypropylene, continuous fiber reinforced thermoplastic composites, melt blown and radiation-resistant polypropylene, radioactive medical isotopes, and hospital and nuclear drug products. Founded in 1994 and headquartered in Shenzhen, China, CGN Nuclear Technology Development operates primarily in China within the nuclear technology development, nuclear medical equipment, and industrial accelerator sectors. Recently, CGN Nuclear Technology Development inaugurated its proton therapy equipment manufacturing base with the first unit produced in November 2024, ready for dispatch to customers. The company continues to expand its production capabilities for advanced nuclear medical technologies. There has been a leadership change with the chairman resigning in early 2025 due to work adjustments. CGN has also been actively involved in strategic cooperation, including partnering with international companies for technical development in nuclear technologies. The firm emphasizes innovation with significant investments in research and development to enhance its competitiveness in the nuclear and medical accelerator industries. It maintains a focus on expanding its product range and improving customer service capacities while supporting green energy and nuclear safety initiatives within China and globally. These developments align with CGN's broader objective of strengthening its position as a key player in nuclear technology and associated high-tech sectors in both domestic and international markets.